Chimeric Antigen Receptor (CAR) T-cells: A Revolution in Immunotherapy
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cancer Vaccines and Immunotherapy".
Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 278
Special Issue Editor
2. Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA
Interests: antibody-drug conjugate; cancer immunology; drug delivery; nanoparticles
Special Issue Information
Dear Colleagues,
Chimeric antigen receptor T-cell (CAR-T) therapies have demonstrated remarkable potential in the treatment of different cancer types, especially hematological malignancy. Despite its high clinical response rate, CAR-T treatment still faces critical challenges such as antigen escape, on-target off-tumor toxicities, and immune suppression. There is an urgent need to overcome these limitations in order to expand CAR-T applications.
To achieve a more extensive understanding of recent scientific knowledge and current trends in CAR-T therapy development, this Special Issue focuses on recent scientific and technical progress in this field, especially in the endeavor to conquer the aforementioned challenges. We invite authors to contribute original reports, original observations, or reviews that highlight (i) target selection, (ii) strategies to overcome current CAR-T limitations, (iii) the mechanisms/cellular pathways behind the limitations, and (iv) recent advances in novel CAR-T development.
We look forward to receiving your contributions.
Dr. Jiawei Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- chimeric antigen receptor T-cell (CAR-T) therapies
- hematological malignancies
- immunotherapy
- CAR-T-associated side-effects
- tumor microenvironment
- CAR-T-associated immunogenicity
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
